Curanex Pharmaceuticals Inc 8-K

What Happened
Curanex Pharmaceuticals announced that Chief Financial Officer and Treasurer Haiyan Yang resigned effective December 31, 2025. The company appointed Wanjun Zhang as CFO and Treasurer effective January 1, 2026, and entered a two-year consulting agreement with him beginning that date.

Key Details

• Resignation: Haiyan Yang resigned as CFO and Treasurer, effective December 31, 2025; not due to any disagreement with the company’s operations, policies or practices.
• Appointment: Wanjun Zhang, age 52, appointed CFO and Treasurer effective January 1, 2026. He has 20+ years of finance and accounting experience, including finance director roles and work for a former Nasdaq-listed SEC reporting company.
• Agreement & pay: Company entered a consulting agreement dated December 31, 2025, with an initial two-year term starting January 1, 2026; compensation is $20,000 per year.
• Independence and disclosures: Filing states no arrangements or understandings with third parties regarding the appointment, no family relationships with company officers or directors, and no reportable related-party transactions under Item 404(a).

Why It Matters
This filing documents a leadership change in the company’s financial reporting function and transfers responsibility for accounting oversight, SEC filings, internal audit coordination, and investor relations to Mr. Zhang. The consulting agreement and modest annual fee ($20,000) are disclosed; investors can expect continuity in duties but should note the change in personnel responsible for Curanex’s financial controls and public filings. The consulting agreement is filed as an exhibit to the 8-K.